HomeCompareBDX vs MA

BDX vs MA: Dividend Comparison 2026

BDX yields 2.27% · MA yields 0.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MA wins by $470.3K in total portfolio value· pulled ahead in Year 4
10 years
BDX
BDX
● Live price
2.27%
Share price
$154.69
Annual div
$3.51
5Y div CAGR
13.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$1,058.14
Full BDX calculator →
MA
MA
● Live price
0.64%
Share price
$494.00
Annual div
$3.15
5Y div CAGR
91.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$497.2K
Annual income
$341,049.48
Full MA calculator →

Portfolio growth — BDX vs MA

📍 MA pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDXMA
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDX + MA cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDX pays
MA pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDX
Annual income on $10K today (after 15% tax)
$192.91/yr
After 10yr DRIP, annual income (after tax)
$899.42/yr
MA
Annual income on $10K today (after 15% tax)
$54.20/yr
After 10yr DRIP, annual income (after tax)
$289,892.06/yr
At 15% tax rate, MA beats the other by $288,992.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDX + MA for your $10,000?

BDX: 50%MA: 50%
100% MA50/50100% BDX
Portfolio after 10yr
$262.1K
Annual income
$171,053.81/yr
Blended yield
65.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MA right now

BDX
Analyst Ratings
16
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$193.80
+25.3% upside vs current
Range: $170.00 — $215.00
Altman Z
2.1
Piotroski
8/9
MA
Analyst Ratings
1
Strong
51
Buy
12
Hold
Consensus: Buy
Price Target
$667.33
+35.1% upside vs current
Range: $610.00 — $739.00
Altman Z
9.7
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDX buys
12
MA buys
8
PoliticianChamberTickerTypeAmountDate
Sheldon Whitehouse🏛 Senate$MA▼ Sell$1,001 - $15,0002026-02-23
Markwayne Mullin🏛 Senate$MA▲ Buy$50,001 - $100,0002025-12-29
Markwayne Mullin🏛 Senate$MA▲ Buy$50,001 - $100,0002025-12-29
Michael McCaul🏢 House$MA▼ Sell$1,001 - $15,0002025-10-27
Gilbert Cisneros🏢 House$MA▲ Buy$1,001 - $15,0002025-10-17
Ro Khanna🏢 House$BDX▲ Buy$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MA▼ Sell$1,001 - $15,0002025-09-23
Ro Khanna🏢 House$MA▲ Buy$1,000 - $15,0002025-08-04
Lisa McClain🏢 House$BDX▼ Sell$1,001 - $15,0002025-06-24
Lisa McClain🏢 House$MA▼ Sell$1,001 - $15,0002025-06-24
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDXMA
Forward yield2.27%0.64%
Annual dividend / share$3.51$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.5%91.8%
Portfolio after 10y$26.9K$497.2K
Annual income after 10y$1,058.14$341,049.48
Total dividends collected$5.7K$463.2K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusBuyBuy
Analyst price target$193.80$667.33

Year-by-year: BDX vs MA ($10,000, DRIP)

YearBDX PortfolioBDX Income/yrMA PortfolioMA Income/yrGap
1$10,958$257.59$10,822$122.30+$136.00BDX
2$12,024$299.40$11,817$237.26+$207.00BDX
3$13,214$348.50$13,109$464.38+$105.00BDX
4← crossover$14,545$406.26$14,950$923.39$405.00MA
5$16,038$474.35$17,884$1,887.66$1.8KMA
6$17,715$554.80$23,183$4,047.78$5.5KMA
7$19,606$650.06$34,212$9,405.89$14.6KMA
8$21,741$763.12$61,488$24,880.97$39.7KMA
9$24,161$897.64$145,949$80,157.01$121.8KMA
10$26,910$1,058.14$497,215$341,049.48$470.3KMA

BDX vs MA: Complete Analysis 2026

BDXHealthcare

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Full BDX Calculator →

MAFinancials

Mastercard Incorporated, a technology company, provides transaction processing and other payment-related products and services in the United States and internationally. It facilitates the processing of payment transactions, including authorization, clearing, and settlement, as well as delivers other payment-related products and services. The company offers integrated products and value-added services for account holders, merchants, financial institutions, businesses, governments, and other organizations, such as programs that enable issuers to provide consumers with credits to defer payments; prepaid programs and management services; commercial credit and debit payment products and solutions; and payment products and solutions that allow its customers to access funds in deposit and other accounts. It also provides value-added products and services comprising cyber and intelligence solutions for parties to transact, as well as proprietary insights, drawing on principled use of consumer, and merchant data services. In addition, the company offers analytics, test and learn, consulting, managed services, loyalty, processing, and payment gateway solutions for e-commerce merchants. Further, it provides open banking and digital identity platforms services. The company offers payment solutions and services under the MasterCard, Maestro, and Cirrus. Mastercard Incorporated was founded in 1966 and is headquartered in Purchase, New York.

Full MA Calculator →
📬

Get this BDX vs MA comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDX vs SCHDBDX vs JEPIBDX vs OBDX vs KOBDX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.